Ophthalmic formulations of cetirizine and methods of use
View Patent ↗The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
1. A topical ophthalmic formulation consisting essentially of 0.24% cetirizine (w/v), 1% Polyethylene Glycol 400, NF, 0.2% Dibasic Sodium Phosphate, Anhydrous, USP, 0.25% Hypromellose, USP, 0.1% Polysorbate 80, NF, 1.8% Glycerin, USP, 0.01% Benzalkonium Chloride, NF, 0.025% Edetate Disodium, USP, and Purified Water, USP, wherein the formulation has a pH 6.8-7.2 and does not contain a cyclodextrin or other solubilizing compound.
2. The formulation of claim 1 , wherein the cetirizine is present as cetirizine hydrochloride or dihydrochloride.
3. The formulation of claim 1 , wherein the formulation is an aqueous formulation, an ointment, an oil, a suspension, an emulsion, or incorporated as a drug delivery device.